EWEdwards Lifesciences

Health care · Medical Devices · NYSE

Edwards Lifesciences Corporation is the leading global structural heart innovation company, driven by a passion to improve patient lives. 10-K, Item 1

Employees: 16,000
Headquarters: Irvine, CA
CEO: Bernard J. Zovighian
Next results: around Feb 9, 2027

Compare with peers → Embed

RevenueFY2016–25 $6.1B+11.5% Highest in 10 years 10-K FY2025 · XBRL Net incomeFY2016–25 $1.1B−74.3% FY2024: $4.2B 10-K FY2025 · XBRL Free cash flowFY2016–25 $1.3B+360.5% FY2024: $289.9M 10-K FY2025 · XBRL Operating marginFY2016–25 20.8%−4.5 pts 25.3% in FY2016 10-K FY2025 · XBRL

What changed

10-K filed Feb 25, 2026 against Feb 28, 2025

Area	What changed	Source
Risk factors	11 new paragraphs, nothing like them in the previous 10-K	10-K Item 1A
Accounting checks	11 other checks clear	10-K · XBRL
Insiders	No open-market buys in the last 90 days	Form 4
Filings	2 in the last 30 days	EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

What's new, in their words

10-K filed Feb 25, 2026

Paragraphs in Risk Factors that were not in the 10-K filed 2025-02-28. Quoted as filed.

Our use of, or our failure to effectively and timely utilize, emerging technologies, including AI, could adversely impact our business and financial results. We use AI and other emerging technologies in various facets of our operations and our business. The legal and regulatory landscape surrounding AI technologies is rapidly evolving…
10-K, Item 1A

All 11 new paragraphs →

Accounting checks

latest 10-K

11 of 11 clear 0 worth a look. Checks, not verdicts.

✓
Receivables +8.3% vs revenue +11.5% (-3.3 pts)
✓
Cash from operations $1.6B vs net income $1.1B (FY ending 2025-12-31)
✓
Inventory +3.6% vs revenue +11.5% (-7.9 pts)
✓
Same auditor in both 10-Ks: PricewaterhouseCoopers LLP
✓
No statement of substantial doubt about going concern
✓
No 8-K item 4.02 in the last 2 years
✓
No NT 10-K or NT 10-Q in the last 2 years
✓
No longer listed: Acquisition of Endotronix, Inc. - Valuation of the Developed Technology; Acquisition of Innovalve Bio Medical Ltd. - Valuation of the IPR&D. Same as last year: Uncertain Tax Positions Related to Intercompany Transfer Pricing
✓
No sentence in the 10-K concludes that controls were not effective because of a material weakness
✓
No 8-K item 2.06 in the last 2 years
✓
No 8-K item 1.03 in the last 2 years

How each check works, with sources →

In the last 30 days

All filings →

Nov 4, 20268-K Quarterly results 8-K item 2.02
Nov 4, 202610-Q Quarterly report (10-Q) period ended Sep 30, 2026

Get an email when this changes: new risk paragraphs, accounting items, insider purchases, a new 10-K or 10-Q. RSS feed

Work on EW in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/EW/export.csv") into a cell.